Results 151 to 160 of about 12,305 (210)
European Journal of Haematology, Volume 117, Issue 5, Page 1265-1274, November 2026.In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri +11 more
wiley +1 more source
Headache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2337-2349, November/December 2026.Abstract Objectives/Background Cluster headache (CH) has historically been considered a male‐dominated disorder, suggesting a role for androgens in its pathophysiology. We aimed to evaluate hormone profiles and symptoms of androgen deficiency in CH.
Willemijn C. Naber +7 more
wiley +1 more source
Lipoprotein(a), Endothelial Dysfunction and Cardiovascular Disease
Journal of Cellular and Molecular Medicine, Volume 30, Issue 21, November 2026.ABSTRACT Lipoprotein(a) (Lp(a)) is a particle similar to low‐density lipoprotein cholesterol and is associated with apolipoprotein (A). High Lp(a) levels are a genetic, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Endothelial cells, which form the continuous lining of the cardiovascular system, are crucial for vascular ...
Xianghui Zhou +5 more
wiley +1 more source
The FASEB Journal, Volume 40, Issue 20, 31 October 2026.BMP‐3 is synthesized as a proprotein that is cleaved by furin/proprotein convertases (PC) to release the biologically active mature ligand. Although never experimentally verified, the BMP‐3 ligand is recorded as C‐terminal Q363‐R472 (110 amino acids) approximately 16 kDa.
David E. Phelan +4 more
wiley +1 more source
NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis
British Journal of Haematology, Volume 209, Issue 5, Page 2331-2334, November 2026.
R. Van Dijck +8 more
wiley +1 more source
Development of a specific activin antagonist for therapeutic applications
Activin is a key regulator of homeostasis in several organs and tissues, including ovaries, testes, liver and skin, and alterations in activin s activity can result in fibrosis, cachexia and cancer.
core
Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Theriogenology, 1997 Activin was originally isolated from follicular fluid as a factor stimulating FSH from the pituitary. Recent studies also suggest a local role for activin in the development of preantral and early antral follicles. In the present study, activin and activin receptor immunoreactivity are shown in oocyte and granulosa cells of bovine preantral follicles ...
J R Figueiredo +2 more
exaly +4 more sources
, 2007 Activin A is a growth factor composed of two betaA subunits belonging to the transforming growth factor beta (TGF-beta) superfamily of dimeric proteins. The biological activity of activin A is mediated by two different types of receptors, the type I (ARI and ARIB) and the type II receptors (ARII and ARIIB), and by two activin-binding proteins ...
Florio, Pasquale +3 more
openaire +4 more sources